at www.emdgroup.com or in Versums Annual Report on Form
10-K
filed with the U.S. Securities and Exchange Commission (the SEC) for the
fiscal year ended on September 30, 2018 and Versums other filings with the SEC, which are available at http://www.sec.gov and Versums website at www.versummaterials.com. Except as otherwise required by law, Versum assumes no
liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date hereof.
Additional Important Information and Where to Find It
This communication relates to the proposed merger transaction involving Versum and Merck KGaA, Darmstadt, Germany. In connection with the proposed merger,
Versum and Merck KGaA, Darmstadt, Germany have filed relevant materials with the SEC, including Versums definitive proxy statement on Schedule 14A (the Proxy Statement), and may file other relevant materials with the SEC. This
communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, and is not a substitute for the Proxy Statement or any other document that Versum or Merck KGaA,
Darmstadt, Germany, has filed or may file with the SEC or have sent or may send to Versums stockholders in connection with the proposed merger. STOCKHOLDERS OF VERSUM ARE URGED TO READ ALL RELEVANT DOCUMENTS THAT HAVE BEEN OR MAY BE FILED WITH
THE SEC, INCLUDING THE PROXY STATEMENT, BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED MERGER. Investors and security holders may obtain the documents free of charge at the SECs web site, http://www.sec.gov, or Versums
website at http://investors.versummaterials.com or by phone at
484-275-5907.
Participants in Solicitation
Versum, Merck KGaA,
Darmstadt, Germany and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from the holders of Versum common stock in respect of the proposed transaction. Information about the directors
and executive officers of Versum is set forth in Versums Annual Report on Form
10-K
for the fiscal year ended September 30, 2018, which was filed with the SEC on November 21, 2018, and the
proxy statement for Versums 2019 annual meeting of stockholders, which was filed with the SEC on December 20, 2018. Information about the directors and executive officers of Merck KGaA, Darmstadt, Germany is set forth on Schedule I of the
Schedule 14A filed by Merck KGaA, Darmstadt, Germany with the SEC on March 22, 2019. Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or
otherwise, will be contained in the Proxy Statement and other relevant materials to be filed with the SEC in respect of the proposed transaction when they become available.